VolitionRx Granted Its Third U.S. Patent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/18/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Brazil's Bolsonaro, Lula face off in first debate as supporters fill streets
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Volitionrx Limited (VNRX) Chief Medical Officer to Assume Full-Time Role
January 5, 2016 7:09 AM ESTVolitionrx Limited (NYSE: VNRX) announced that Jason Terrell, MD transitioned to full-time status as Chief Medical Officer and Head of U.S. Operations, effective January 1, 2016. Dr. Terrell has served in a part-time capacity as the Company's Chief Medical Officer and Head of U.S. Operations since March 2013. Dr. Terrell will continue to lead and coordinate VolitionRx's U.S. operations in preparation for initial market entry of the Company's NuQ® blood tests for cancer in the U.S. and worldwide.VolitionRx Limited"The recent results of clinical trials by VolitionRx have been so... More



